|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Hospira, Inc. (NYSE: HSP), a specialty pharmaceutical and medication delivery company sellng primarily to hospitals. |
|---|---|
| Transferring Party | Mayne Pharma Limited (ASX: MYP), an Australian-based specialty generic injectable pharmaceuticals company. |
| Sector | Biopharmaceuticals |
| Date | February 2, 2007 |
| Analysis Doubles Hospira’s international sales and vastly upgrades its fledgling international distribution network. About 75% of Mayne’s $600m in annual sales are outside the U.S., with half its sales coming from Europe. Also bolsters Hospira’s generic injectable drug business, which accounted for about one-third of its sales and is among its most profitable segments. Deal value - $2.0b. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |